Shares of Neurometrix Inc (NASDAQ:NURO) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports.
Brokerages have set a 1-year consensus target price of $50.00 for the company and are expecting that the company will post ($1.80) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Neurometrix an industry rank of 108 out of 255 based on the ratings given to its competitors.
NURO has been the subject of a number of recent research reports. ValuEngine downgraded Neurometrix from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. Zacks Investment Research downgraded Neurometrix from a “buy” rating to a “hold” rating in a research note on Thursday, December 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Neurometrix in a research note on Friday, October 18th.
Shares of NURO traded up $0.36 during midday trading on Friday, reaching $4.75. 291,865 shares of the stock were exchanged, compared to its average volume of 225,304. Neurometrix has a 12-month low of $2.52 and a 12-month high of $12.00. The firm has a 50 day simple moving average of $4.31 and a 200-day simple moving average of $1.67. The company has a market cap of $4.30 million, a price-to-earnings ratio of -0.85 and a beta of 0.81.
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
Featured Story: What is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.